Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - June 2011

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for June 2011 (PDF).

This issue contains drug safety information advising clinicians how to manage bisphosphonate therapy in light of rare atypical femoral fractures. It is suggested that in the event of an atypical femoral fracture the benefits and risks of treatment are reassessed and that treatment can be discontinued while the patient is evaluated.

Clinicians are also advised that the optimum treatment duration for osteoporosis has not been evaluated and therefore continued treatment should be re-evaluated periodically but particularly after 5 or more years of use.

The drug safety section also informs clinicians about recent epidemiological studies that have shown that the risk of venous thromboembolism (VTE) for drospirenone containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs. It is also noted that the risk may be similar to COCs that contain desogestrel or gestodene (so-called ‘third generation’ pills).

The risk of VTE is still small, and less than the risk associated with pregnancy however clinicians should be aware of this information when discussing the most suitable type of contraceptive.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - June 2011' on Email Share 'Drug Safety Update - June 2011' on Delicious Share 'Drug Safety Update - June 2011' on Digg Share 'Drug Safety Update - June 2011' on Facebook Share 'Drug Safety Update - June 2011' on Google+ Share 'Drug Safety Update - June 2011' on reddit Share 'Drug Safety Update - June 2011' on StumbleUpon Share 'Drug Safety Update - June 2011' on Twitter

atomic-wealth

One Comments to “Drug Safety Update - June 2011”

  1. [...] increased two or three fold but is still lower than the risk of VTE associated with pregnancy. The Drug Safety Update in June also reviewed these [...]

    Pingback by Prescribing Advice For GPs » MeReC Extra 50 — August 26, 2011 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,316 spam comments.

atomic-wealth
fond-illness
summer